Chloroprocaine 2% Injectable Solution — Competitive Intelligence Brief

Chloroprocaine 2% Injectable Solution (Chloroprocaine 2% Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Oncology.

phase 2 Local anesthetic Voltage-gated sodium channels Oncology Small molecule

Target snapshot

Chloroprocaine 2% Injectable Solution (Chloroprocaine 2% Injectable Solution) — Sintetica SA. Local anesthetic by blocking sodium channels

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chloroprocaine 2% Injectable Solution TARGET	Chloroprocaine 2% Injectable Solution	Sintetica SA	phase 2	Local anesthetic	Voltage-gated sodium channels
All registered antiepileptic drugs	All registered antiepileptic drugs	UMC Utrecht	marketed	Antiepileptic drugs (heterogeneous class)	Multiple targets including voltage-gated sodium channels, GABA receptors, calcium channels, SV2A, and others depending on specific agent
prilocaine 1%	prilocaine 1%	Helios Research Center	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Bupivacaine Spinal 0,5% Heavy - bolus	Bupivacaine Spinal 0,5% Heavy - bolus	Centre of Postgraduate Medical Education	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Heavy Bupivacaine	Heavy Bupivacaine	Diskapi Yildirim Beyazit Education and Research Hospital	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Standard dose oxcarbazepine	Standard dose oxcarbazepine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
Standard dose lamotrigine	Standard dose lamotrigine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class